Profile
| Metric | Value |
|---|---|
| Full Name | Royalty Pharma plc |
| Ticker | NASDAQ: RPRX |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | royaltypharma.com |
| Employees | 75 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $40.17 | |
| Price, 1D Change | -0.22% | |
| Market Cap | $17B | |
| TTM Dividend Yield | 2.19% | |
| PE Ratio | 22.97 | |
| Beta | 0.30 | |
| Revenue | $2B | |
| Revenue, 1Y Change | -3.86% | |
| EPS | $1.91 | |
| EPS, 1Y Change | -24.54% |
Chart
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | $0.22 | |
| Next Ex-Dividend | $0.24 | |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $1.91 | |
| EPS Estimate | $4.64 | |
| EPS Est. Change | +142.54% | |
| Revenue | $2.26B | |
| Revenue Estimate | $3.18B | |
| Revenue Est. Change | +40.51% | |
| Current Price | $40.17 | |
| Price Target | - | $45.00 |
| Price Tgt. Change | - | +12.02% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $4.03 | $2.53 | -37.13% | |
| $4.05 | $1.91 | -52.78% | |
| $4.64 | N/A | +142.54% | |
| $5.05 | N/A | +164.06% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $2.79B | $2.35B | -15.64% | |
| $2.70B | $2.26B | -16.32% | |
| $3.18B | N/A | +40.51% | |
| $3.30B | N/A | +45.75% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +53.32% | |
| Price, 3Y | +2.47% | |
| Market Cap, 1Y | +46.88% | |
| Market Cap, 3Y | -1.21% | |
| Revenue, 1Y | -3.86% | |
| Revenue, 3Y | -1.13% | |
| EPS, 1Y | -24.54% | |
| EPS, 3Y | +27.97% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $40.17 | |
| SMA 200 | $35.89 | |
| SMA 200 vs Price | -10.66% | |
| SMA 50 | $39.05 | |
| SMA 50 vs Price | -2.79% | |
| Beta | 0.30 | |
| ATR | $0.84 | |
| 14-Day RSI | 57.59 | |
| 10-Day Volatility | 24.83% | |
| 1-Year Volatility | 22.87% |
Dividends
| Metric | Date | Value |
|---|---|---|
| Last Paid | $0.22 | |
| Upcoming | $0.24 | |
| Dividend Yield | 2.09% | |
| Total Dividend | $0.84 | |
| Dividends Paid | $376.47M | |
| Payout Ratio | 28.29% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $2.26B | |
| EPS | $1.91 | |
| Gross Profit | $0.00 | |
| Gross Margin | 0.00% | |
| Operating Profit | $1.29B | |
| Operating Margin | 57.10% | |
| Net Income | $1.33B | |
| Net Margin | 58.79% | |
| EBITDA | $1.29B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 1.10 | |
| Current Ratio | 1.44 | |
| Quick Ratio | 1.44 | |
| - | ||
| F-Score | 7 | |
| Altman Z-Score | 1.92 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 22.97 | |
| PS Ratio | 7.30 | |
| PB Ratio | 2.68 | |
| EV/EBITDA | 16.41 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $6.95B | |
| Cash & Equivalents | $987.23M | |
| Total Assets | $18.22B | |
| Current Assets | $1.80B | |
| Total Liabilities | $7.88B | |
| Current Liabilities | $1.25B | |
| Total Debt | $7.61B | |
| Short Term Debt | $997.77M | |
| Accounts Payable | $13.37M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $1.40B | |
| Operating Expenses | -$1.29B | |
| Cost Of Goods Sold | - | |
| SG&A | $0.00 | |
| D&A | $0.00 | |
| Interest Expense | $0.00 | |
| Income Tax | $0.00 |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $2.79B | |
| CFI | -$2.70B | |
| CFF | $356.04M | |
| Capex | $2.52B | |
| Free Cash Flow | $268.93M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| TD Cowen | → | |
| Morgan Stanley | → | |
| Goldman Sachs | ||
| Citigroup | → | |
| Morgan Stanley | → | |
| Citigroup | → | |
| Goldman Sachs | → | |
| Morgan Stanley | → | |
| UBS | → | |
| B of A Securities | → |
Analyst sentiment
Institutional ownership
Screeners with RPRX
Data Sources & References
- RPRX Official Website www.royaltypharma.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1802768/000180276825000114/0001802768-25-000114-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1802768/000180276825000010/0001802768-25-000010-index.htm
- RPRX Profile on Yahoo Finance finance.yahoo.com/quote/RPRX
- RPRX Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/rprx
FAQ
What is the ticker symbol for Royalty Pharma plc?
The ticker symbol for Royalty Pharma plc is NASDAQ:RPRX
Does Royalty Pharma plc pay dividends?
Yes, Royalty Pharma plc pays dividends. The last payment was $0.22, with an ex-dividend date on November 14, 2025
What sector is Royalty Pharma plc in?
Royalty Pharma plc is in the Healthcare sector
What industry is Royalty Pharma plc in?
Royalty Pharma plc is in the Biotechnology industry
What country is Royalty Pharma plc based in?
Royalty Pharma plc is headquartered in United States
When did Royalty Pharma plc go public?
Royalty Pharma plc initial public offering (IPO) was on June 16, 2020
Is Royalty Pharma plc in the S&P 500?
No, Royalty Pharma plc is not included in the S&P 500 index
Is Royalty Pharma plc in the NASDAQ 100?
No, Royalty Pharma plc is not included in the NASDAQ 100 index
Is Royalty Pharma plc in the Dow Jones?
No, Royalty Pharma plc is not included in the Dow Jones index
When was Royalty Pharma plc last earnings report?
Royalty Pharma plc's most recent earnings report was on November 5, 2025
When does Royalty Pharma plc report earnings?
The next expected earnings date for Royalty Pharma plc is February 10, 2026
